<SEC-DOCUMENT>0001193125-23-148409.txt : 20230518
<SEC-HEADER>0001193125-23-148409.hdr.sgml : 20230518
<ACCEPTANCE-DATETIME>20230518185128
ACCESSION NUMBER:		0001193125-23-148409
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230518
DATE AS OF CHANGE:		20230518

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		23937502

	BUSINESS ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BCIP Life Sciences Associates, LP
		CENTRAL INDEX KEY:			0001702921
		IRS NUMBER:				814329455
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		6175162878

	MAIL ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><own:edgarSubmission xmlns:com="http://www.sec.gov/edgar/common" xmlns:own="http://www.sec.gov/edgar/ownership">
  <own:headerData>
    <own:submissionType>144</own:submissionType>
    <own:filerInfo>
      <own:filer>
        <own:filerCredentials>
          <own:cik>0001702921</own:cik>
          <own:ccc>XXXXXXXX</own:ccc>
        </own:filerCredentials>
      </own:filer>
      <own:liveTestFlag>LIVE</own:liveTestFlag>



    </own:filerInfo>
  </own:headerData>
  <own:formData>
    <own:issuerInfo>
      <own:issuerCik>0001029142</own:issuerCik>
      <own:issuerName>DYNAVAX TECHNOLOGIES CORP</own:issuerName>
      <own:secFileNumber>001-34207</own:secFileNumber>
      <own:issuerAddress>
        <com:street1>2100 Powell Street</com:street1>
        <com:street2>Suite 720</com:street2>
        <com:city>Emeryville</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>94608</com:zipCode>
      </own:issuerAddress>
      <own:issuerContactPhone>510-848-5100</own:issuerContactPhone>
      <own:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>BCIP LIFE SCIENCES ASSOCIATES, LP</own:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <own:relationshipsToIssuer>
        <own:relationshipToIssuer>Affiliate</own:relationshipToIssuer>
      </own:relationshipsToIssuer>
    </own:issuerInfo>
    <own:securitiesInformation>
      <own:securitiesClassTitle>Common Stock</own:securitiesClassTitle>
      <own:brokerOrMarketmakerDetails>
        <own:name>Goldman Sachs &amp; Co. LLC</own:name>
        <own:address>
          <com:street1>200 West Street</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10282</com:zipCode>
        </own:address>
      </own:brokerOrMarketmakerDetails>
      <own:noOfUnitsSold>92855</own:noOfUnitsSold>
      <own:aggregateMarketValue>1033476.00</own:aggregateMarketValue>
      <own:noOfUnitsOutstanding>128489060</own:noOfUnitsOutstanding>
      <own:approxSaleDate>05/18/2023</own:approxSaleDate>
      <own:securitiesExchangeName>Nasdaq</own:securitiesExchangeName>
    </own:securitiesInformation>
    <own:securitiesToBeSold>
      <own:securitiesClassTitle>Common Stock</own:securitiesClassTitle>
      <own:acquiredDate>08/12/2019</own:acquiredDate>
      <own:natureOfAcquisitionTransaction>Purchase of Common Stock in an underwritten public offering</own:natureOfAcquisitionTransaction>
      <own:nameOfPersonfromWhomAcquired>Underwriter</own:nameOfPersonfromWhomAcquired>
      <own:isGiftTransaction>N</own:isGiftTransaction>
      <own:amountOfSecuritiesAcquired>698734</own:amountOfSecuritiesAcquired>
      <own:paymentDate>08/12/2019</own:paymentDate>
      <own:natureOfPayment>Cash</own:natureOfPayment>
    </own:securitiesToBeSold>
    <own:securitiesToBeSold>
      <own:securitiesClassTitle>Common Stock</own:securitiesClassTitle>
      <own:acquiredDate>05/27/2020</own:acquiredDate>
      <own:natureOfAcquisitionTransaction>Purchase of Common Stock in an underwritten public offering</own:natureOfAcquisitionTransaction>
      <own:nameOfPersonfromWhomAcquired>Underwriter</own:nameOfPersonfromWhomAcquired>
      <own:isGiftTransaction>N</own:isGiftTransaction>
      <own:amountOfSecuritiesAcquired>92855</own:amountOfSecuritiesAcquired>
      <own:paymentDate>05/27/2020</own:paymentDate>
      <own:natureOfPayment>Cash</own:natureOfPayment>
    </own:securitiesToBeSold>
    <own:nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</own:nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <own:noticeSignature>
      <own:noticeDate>05/18/2023</own:noticeDate>
      <own:signature>/s/ Andrew Hack, as Authorized Signatory of Boylston Coinvestors, LLC</own:signature>
    </own:noticeSignature>
  </own:formData>
</own:edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
